Further survival analysis revealed that HNSCC patients with TP53 mutations in the high TLS signature group had superior OS (P < 0.001) and PFS (P=0.005) than those in the low group, while patients with TP53 wild-type had no discernible difference (Fig. 5). The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.